GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.

Altimmune's pemvidutide showed strong MASH resolution and good tolerability in IMPACT, but fibrosis data fell short. See why ...

What will Boston Pharmaceuticals CEO Sophie Kornowski do now that the company is selling off its pipeline and winding down ...

(RTTNews) - GSK plc (GSK, GSK.L) announced Thursday it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025 ...

GSK plc announced the completion of its previously announced acquisition of efimosfermin alfa from Boston Pharmaceuticals. Efimosfermin is a phase III-ready, potential best-in-class investigational ...

"GSK acquires efimosfermin alfa from Boston Pharma for $2bn" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH.

Elevated long-chain to very long-chain ceramide ratios emerged as potential biomarkers linked to disease severity across IBD, PSC, and PSC-IBD.

Gilead is mounting a bid to tighten its grip on the HIV market. Having secured approval for twice-yearly HIV prevention product Yeztugo, the company has a shot at wresting more market share from GSK ...

The committee has alleged that it had information the former Pfizer executive, after going to work for British drugmaker GSK, told his colleagues that Pfizer had delayed announcing its Covid ...